期刊文献+

以去脂体重为标准计算静脉全麻诱导剂量对重度肥胖病人的影响 被引量:8

Effect of lean body weight as a criterion to calculate intravenous induction dose in general anesthesia for severe obese patients
下载PDF
导出
摘要 目的探讨重度肥胖病人以去脂体重为标准计算全麻静脉诱导剂量对气管插管心血管反应。方法选取ASAI~II级、年龄18~60岁、体重指数(BMI)≥40、手术时间<2小时,择期在全麻下行普通外科与骨科手术的患者30例,按照全麻诱导用药剂量的计算方法随机分为三组:去脂体重给药组(LBW组),总体重给药组(TBW组)和理想体重给药组(IBW组),患者均采用静脉麻醉诱导。取入室后前三个收缩压(SBP)、舒张压(DBP)和心率(HR)的平均值作为基础值(T1),分别记录并比较各组患者麻醉诱导后插管前(T2)、插管后即刻(T3)的HR、SBP和DBP以及拔管时间(术毕至拔管的时间),计算并比较各组心率与收缩压的乘积(Cardiac rate-pressure product,RPP),比较各组不良反应的发生情况。结果 (1)在T2时刻,与T1比较,TBW组患者SBP、DBP和HR下降的幅度明显大于LBW组和IBW组(P<0.01);(2)在T3时刻,与T1比较,TBW组和LBW组患者的SBP、DBP和HR均有所下降,且TBW组下降的幅度明显大于LBW组(P<0.01);而IBW组患者的SBP、DBP和HR均有所升高,且升高的幅度大于15%(P<0.01);(3)不良反应的发生情况:三组比较,SBP升高>30%、HR>100次/min和RPP>12000的发生率为IBW组最高(60%、50%、80%,P<0.01);SBP下降>30%和HR<60次/min的发生率均为TBW组最高(70%、50%,P<0.01);(4)三组比较,拔管时间TBW组最长(26.2±12.5min,P<0.01)。结论对于无基础疾病的重度肥胖病人,以LBW作为标准计算静脉麻醉诱导剂量对循环的影响小,不良反应发生率低,苏醒快,更具合理性。 Objective To investigate the cardiovascular response and extubation time of severe obese patients undergoing tracheal intubation by using lean body weight (LBW) as a criterion to calculate intravenous induction dose. Methods Thirty patients, ASA Ⅰ~Ⅱ, aged from 18 to 60 years old, BMI〉40, who were scheduled to perform general and orthopedic surgery undergoing general anesthesia,were involved in this study. Patients who were given anesthetics according to their lean body weight (LBW), total body weight (TBW) and ideal body weight (IBW), were assigned into 3 groups:group LBW, groupTBW and groupIBW respectively. The average of three record of systolic pressure (SBP), diastolic pressure (DBP) and heart rate (HR) were taken as base values (T1). The SBP, DBP and HR of patients in three groups at the moment just before intubation (T2) and at the moment intubation (T3) as well as extubation time (time from the end of surgery to extubation) were recorded. Results (1) The decreases of SBP, DBP and HR in groupTBW at T2 were much more than that in groupLBW and groupIBW compared with T~ (P〈0.01). (2) The decreases of SBP, DBP and HR in groupTBW were much more significant than that in groupLBW at T3 compared with Tt (P 〈 0.01). While those were increased over 15% in grouplBW compared with T1(P〈0.01). (3)The incidence of SBP〉30% baseline, HR〉100/min and RPP〉12000 were highest in grouplBW (60%, 50%, 80%, P〈0.01), the incidence of SBP〈30% baseline and HR〈60/min were highest in group TBW(70%, 50%, P〈0.01). (4) Extubation time in group TBW was longest (26.2±12.5 min, P〈0.01 ) among the three groups. Conclusion LBM may be considered as a reasonable criterion for ASAⅠ~Ⅱ, severe obese patients to calculate the induction dose of intravenous anesthetics since it has less impact on cardiovascular reaction ,lower incidence of adverse reaction and faster recovery from general anesthesia.
出处 《岭南现代临床外科》 2013年第2期103-106,112,共5页 Lingnan Modern Clinics in Surgery
基金 广东省自然科学基金(S2011010004558)
关键词 重度肥胖 去脂体重 麻醉诱导 麻醉苏醒 Severe obesity LBW(Lean body weight) Induction of anesthesia Recovery of anesthesia
  • 相关文献

参考文献13

  • 1赵超,黎梅芳,肖文,李忆琴,赖旻瑶,徐蕾,彭海军,何维熊.成人超重和肥胖症患者每天总热量计算方法的选择[J].广东医学,2004,25(5):577-578. 被引量:9
  • 2Morgan DJ, Bray KM. Lean body mass as a predictor of drugdosage : Implications for Drug Therapy [ J ]. Clinical Pharmac -okinetics, 1994,26(4):292-307.
  • 3Green B, Duffull SB.What is the best size descriptor to usefor pharmacokinetic studies in the obese [J]? Br J Clin Pharma-col, 2004,58(2):119-33.
  • 4Lemmens HJ. Perioperative pharmacology in morbid obesity[J]. Curr Opin Anaesthesiol,2010,3(4) :485-491.
  • 5Casati A, Putzu M. Anesthesia in the obese patient: Pharmac-okinetic considerations[ J]. J Clin Anesth, 2005 ,17(2) : 134-45.
  • 6Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics inthe morbidly obese [J].British Journal of Anaesthesia,2010,105 (SI): il6-i23.
  • 7Leykin Y, Pellis T, Lucca M,et al. The pharmacodynamiceffects of rocuronium when dosed according to real bodyweight or ideal body weight in morbidly obese patients [ J ].Anesth Analg, 2004,99 (4) : 1086-9.
  • 8de Almeida MC, Pedemeiras SG, Chiaroni S, et al.Evaluation of tracheal intubation conditions in morbidly obesepatients: a comparison of succinylcholine and rocuronium[J].Rev Esp Anestesiol Reanim, 2009,56( 1) : 3-8.
  • 9罗慧,郭曲练,王锷.顺式阿曲库铵在肥胖患者中的应用[J].中国现代医学杂志,2010,20(9):1394-1396. 被引量:5
  • 10Ingrande J, Brodsky JB,Lemmens HJ.Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects[J]. Anesth Analg, 2011, 113( 1 ) :57-62.

二级参考文献25

  • 1FUCHS-BUDER T, CLAUDIUS C, SKOVGAARD LT, et al. Good clinical research practice in phannacodynamic studies of neuromuscular blocking agents II: the Stockholm revision[J]. Acta Anaesthesiologiea Scandinavica. 2007, 51(7): 789-808.
  • 2KIROV K, MONTAMED C, DECAILLIOT F, et al. Comparison of the neuromuscular blocking effect of cisatracurium and atracurium on the larynx and the adductor poUicis[J]. Acta Anaesthesiol Stand, 2004, 48 (5): 577-581.
  • 3World Health Organization. Report of a WHO consultation on obesity: preventing and managing the global epidemic [R]. Geneva: World Health Organization, 1997: 1.
  • 4OLKKOLA KT, TAMMISTO T. Quantifying the interaction of rocuronium (Org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental, and isoflurane using closed-loop feedback oontrol of roouronium infusion[J]. Anesth Analg, 1994, 78(4):691-696.
  • 5KIRKEGAARD-NIELSEN H, HELBOHANSEN HS, LINDHOLM P, et al. Anthropometrle variables as predictors for duration of action of atracurium-induced neuromuscular block[J]. Ancsth Analg, 1996,83(5): 1076-1080.
  • 6KISOR DF, SCHMITH VD. Clinical pharmacokinetics of cisatracurium besilate[J]. Clinical Pharmacokinetics, 1999, 36(1): 27-40.
  • 7SCHMIT VD, FIEDLERKELLY J, PHILLIPS L, et al. Prospective use of population pharmaeokinetics/pharmaeodynamics in the development of cisatracurium[J]. 1997, 14(1):91-97.
  • 8LEYKIN Y, PELLIS T, LUCCA M, et al. The effects of cisatracurium on morbidly obese women[J]. Anesth Analg. 2004, 99(4):1090-1094.
  • 9LI JQ, DUAN FM, WANG CY, et al. The dose-effectrelationship of vecuronium on obese patients when administered on lean body weight [J]. The journal of clinical aneshtesiology, 2009, 25(3): 265-266.
  • 10MILLER R. Anaesthesia [M]. Philadelphia: ChurehiU Livingstone, 2000: 412- 490.

共引文献14

同被引文献110

  • 1于健春.肥胖症的多学科综合治疗模式[J].中国医学科学院学报,2010,32(1):1-3. 被引量:21
  • 2曹晖,蒋豪,薛张纲,缪长虹.急性等容量血液稀释对丙泊酚靶控输注的影响[J].临床麻醉学杂志,2005,21(4):224-226. 被引量:9
  • 3佴永军,江志伟,汪志明,李国立,邹志英,黎介寿.胃肠道肿瘤病人术前人体组成分析的研究[J].肠外与肠内营养,2005,12(6):349-351. 被引量:12
  • 4马军,冯宁,阿布都艾尼.吾布力,张世伟,潘勇平,黄永波.双能X线吸收法与生物电阻抗法测量儿童身体成分结果比较[J].中国学校卫生,2007,28(1):3-6. 被引量:12
  • 5Adams JP, Murphy PG. Obesity in anaesthesia and intensive care[J]. Br J Anaesth,2000,85:91-108.
  • 6Casati A, Putzu M. Anesthesia in the obese patient:Pharmaco- kinetic considerations[J]. J Clin Anesth, 2005,17 ( 2 ) : 134- 145.
  • 7Wastila WB, Maehr RB, Turner GL, et al. Comparative phar- macology of cisatracurium (51 W89), atracurium, and five iso- mer in cats [ J]. Anesthesiology, 1996,85 : 169-177.
  • 8Lien CA. Belmont MR, Abalos A, et al. The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia[ J]. An- esthesiology, 1995,82 : 1131-1138.
  • 9Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women[J]. Anesth Analg ,2004,99 : 1090- 1094.
  • 10Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight[ J]. Anesth Analg ,2009,109:787-792.

引证文献8

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部